Get Adobe Flash player


Authors: Sychov R.О.

Pages: 129-136


The aim of the present study was to establish clinical, diagnostic and predicted significance of beta-2-microglobulinuria as a marker of renal damage at essential hypertension and to determine the prevalence of increased urinary beta-2-microglobulin excretion in essential hypertension. The level of beta-2-microglobulinuria was measured in a group of 46 patients with essential hypertension (21 women, 25 men) and in 17 healthy subjects (as control group). Subjects with clinically significant accompanying pathology were carefully excluded during the patient’s selection. The urinary albumin and beta-2-microglobulin excretion were determined by immune-enzyme assay. According to protocol of the study, all patients have undergone examination: clinical, laboratory and instrumental studies, including echocardiography, 24-h ambulatory blood pressure monitoring, investigation of renal hemodynamic by ultrasound Doppler and evaluation renal functional reserve, estimate of glomerular filtration rate according to Cockroft-Gault formula. The beta-2-microglobulinuria value in hypertensive patients was statistically increase from that observed in normal controls. All patients with essential hypertension were distributed into two groups: with normal value (<400 µg/l) and hyperbeta-2-microglobulinuria. In the second group were registered significantly more often violation of intrarenal hemodynamic, left ventricular hypertrophy, proteinuria, decrease of glomerular filtration rate. The method of beta-2-microglobulin evaluation has enough high specificity, sensitivity in diagnostic hypertensive nephropathy. We conclude that the increased urinary beta-2-microglobulin excretion in patients with essential hypertension is a significant marker of the hypertensive nephropathy.

Keywords: beta-2-microglobulinuria, renal reserve, hypertension, myocardial remodeling, microalbuminuria.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text


  1. Zanchetti A, Hansson L, Clement D et al. Benefits and risk of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? JHypertension. 2003;21:797-804.
  2. Almazov VA, Shliakhto EV. [Essential hypertension]. Moscow, 2000. 118 p.
  3. Arutiunov GP, Cherniavskaya TK, Lukicheva TI et al. [Microalbuminuria and the way of its medicamental correction]. Clinical pharmacology and therapy. 1999;3:23-28.
  4. Ruilope LM, Rodicio JL. Renal surrogation in essential hypertension. Clin. Exp. Hypertens. 1999;21(5):609-614.
  5. Valderrabano F, Gomez-Campdera F, Jones E. Hypertension as cause of end-stage renal disease: lessons from international registries. Kidney Int. Suppl. 1998;68:60-66.
  6. Grinstein YI, Shabalin VV. [To the question about index of daily urinary β2-macroglobulin excretion using for kidney functional status assessment in patients with essential hypertension]. Sbornik dokladov III Sibirskoy nauchno-practicheskoi konferencii po aktual’nym voprosam farmakoterapii (kardiologiia) [Proceedings of III Siberian scientific and practical conference regarding actual questions of pharmacotherapy (cardiology)]. Krasnoyarsk, 1998, pp. 53-56.
  7. Preobrazhenskii DV, Marenich FV, Romanova NE. [Microalbuminuria: diagnostic, clinical and prognostic significance]. Russian cardiology journal. 2000;5:49-54.
  8. Caetano EP, Zatz. RТ, Praxedes JN. The clinical diagnosis of hypertensive nephrosclerosis - how reliable is it? Nephrol. Dial. Transplant. 1999;14:288-290.
  9. Epstein M, Parving H, Ruiope LM. Surrogate endpoints and renal protection: focus on microalbuminuria. Blood Pressure. 1997;6(suppl. 2):52-57.
  10. Stephenson JM, Kenny S, Stevens LK et al. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet. Med. 1995;12:149-155.
  11. Agewall S, Wikstrand J, Ljungman S et al. Does microalbuminuria predict cardiovascular events in non-diabetic men with treated hypertension? Risk factor international study group. Am. J. Hypertens. 1995;8:337-343.
  12. Gogin EE. [Essential hypertension]. МMedicinePubl., 1997. 400 p.
  13. BekhetinaVALeonovaMVBelousovYuBRakovSS[Comparative assessment of nephroprotective effect of hypotensive medications in patients with essential hypertension]. Russiancardiologyjournal. 1999;2:8-13.
  14. Evsikov EM, Lyusov VA, Baikova OA et al. [The nature of essential hypertension]. Russiancardiologyjournal. 2000;5:4-12.
  15. Nanchikeeva ML, Konechnaya EYa, Bulanov MN et al. [Possibilities of early diagnostics of kidney involvement in patients with essential hypertension]. Те2004;9:29-34.
  16. Andrushko ІІ, Serkova VK, Pentyuk OO. [Microproteinuria as a marker of essential hypertension development and progression]. Materialy regional’noi naukovo-practychnoi konferencii “Arterial’na hypertensia: vyiavlennia, poshyrenist’, dyspanserizatsiya, profilaktyka ta likuvanniia”. [Proceedings of regional scientific and practical conference “Arterial hypertension: detection, prevalence, health survey, prophylaxis and treatment”]. Ivano-Frankivsk, 2003, p. 43.
  17. PoliakovLMPoteriaevaONPaninLE[Enzyme linked immunosorbent assayА-I and В in the urine of patients with nephrotic syndrome]. Voprosy meditsinskoy khimii. 1999;1:18-22.
  18. Bernard AM, Moreau D, Lauwerys R. Comparison of retinol binding protein and b2-microglobulin determination in urine for early detection of tubular proteinuria. Clin. Chem. Acta. 1982;126:1-7.
  19. VilchinskayaMYuZharovaEANasonovELRatio of humoral immunity indexes and activity of renin-angiotensin-aldosterone system in patients with essential hypertension. Ter. Arkh. 1991;63(4):54-57.
  20. Abraham PA, Mascioli SR, Launer1994;7:965-974.
  21. Leonova MV, Demidova MA, Tarasov AV, Belousov YuB. [Hypotensive, organoprotective and metabolic efficacy of spirapril in patients with essential hypertension]. Ratsional’naya pharmakoterapia v kardiologii. 2005;2:4-8.
  22. Lavrenova TP. [Urinary enzymes and their importance for the diagnosis of kidney lesions (review of the literature)].
  23. Lukomskaia IS, Lavrenova TP, Tomilina NA, Zubkin ML, Fedorova ND. [Diagnostic value of determining neutral alpha-glucosidase and N-acetyl-beta-D-hexosaminidase activity in the urine in kidney pathology]. Vopr Med Khim. 1986;32(5):112-119.